Scopus Biopharma Inc. (SCPS): Business Model Canvas [Jan-2025 Mis à jour]

Dans le monde dynamique de la biotechnologie, Scopus Biopharma Inc. (SCPS) émerge comme une force pionnière, naviguant stratégiquement dans le paysage complexe de la recherche sur les troubles neurologiques et de la thérapeutique des maladies rares. En tirant parti d'une toile de modèle commercial sophistiqué qui entrelace la recherche innovante, des partenariats stratégiques et des capacités scientifiques de pointe, l'entreprise est prête à transformer l'innovation médicale. Leur approche complète s'étend, de la recherche préclinique aux traitements révolutionnaires potentiels, positionnant Scopus comme un acteur potentiellement transformateur dans l'écosystème de la médecine de précision.

Scopus Biopharma Inc. (SCPS) - Modèle commercial: partenariats clés

Accords de recherche collaborative avec les établissements universitaires

Scopus Biopharma Inc. a établi des partenariats de recherche avec les établissements universitaires suivants:

Institution	Focus de recherche	Année de partenariat
École de médecine de l'Université de Miami Miller	Recherche thérapeutique contre le cancer	2022
Université Johns Hopkins	Développement d'immunothérapie	2023

Partenariats potentiels de développement pharmaceutique

Les collaborations actuelles de développement pharmaceutique comprennent:

• Précision Biosciences - Arcus Gene Édition Technologie Collaboration
• Partenariat de recherche axé sur le développement de nouvelles thérapies contre le cancer
• Discussions en cours avec plusieurs sociétés pharmaceutiques pour les accords de licence potentiels

Alliances stratégiques avec des centres de recherche en biotechnologie

Centre de recherche	Type de collaboration	Domaine de recherche
MD Anderson Cancer Center	Collaboration de recherche	Développement de médicaments en oncologie
Moffitt Cancer Center	Partenariat d'essai clinique	Recherche d'immunothérapie

Organisations de fabrication de contrats pour la production de médicaments

Les partenariats de fabrication actuels de Scopus Biopharma:

• Solutions pharmatriques catalennes - Fabrication biologique
• Wuxi Biologics - Capacités de production de thérapie cellulaire
• AGC Biologics - Services de fabrication spécialisés

Investissement total de partenariat de recherche: 3,2 millions de dollars en 2023

Budget d'extension de partenariat projeté pour 2024: 4,5 millions de dollars

Scopus Biopharma Inc. (SCPS) - Modèle d'entreprise: Activités clés

Recherche et développement biopharmaceutique

Scopus Biopharma se concentre sur le développement de nouvelles approches thérapeutiques pour remettre en question les conditions médicales. En 2024, la société a alloué 3,2 millions de dollars aux efforts de recherche et de développement.

Catégorie d'investissement de R&D	Dépenses annuelles
Recherche préclinique	1,5 million de dollars
Préparation des essais cliniques	1,7 million de dollars

Gestion des essais précliniques et cliniques

La société gère plusieurs étapes des essais cliniques avec une équipe de recherche dédiée de 12 professionnels.

• Essais cliniques actifs: 3 études en cours
• Phases des essais: phase I et phase II
• Inscription totale des patients: 87 participants

Découverte de médicaments et innovation thérapeutique

Scopus Biopharma se concentre sur le développement de solutions thérapeutiques innovantes avec un accent spécifique sur les conditions neurologiques et inflammatoires.

Métrique d'innovation	État actuel
Candidats à la drogue active	2 candidats thérapeutiques principaux
Demandes de brevet	4 applications en attente

Développement et protection de la propriété intellectuelle

Stratégie de propriété intellectuelle est essentiel au positionnement concurrentiel de l'entreprise.

• Portfolio total des brevets: 6 brevets enregistrés
• Régions de protection des brevets: États-Unis, Union européenne
• Coûts annuels de gestion de la propriété intellectuelle: 450 000 $

Compliance réglementaire et exécution des essais cliniques

L'adhésion rigoureuse aux normes réglementaires est maintenue tout au long des processus de recherche et de développement.

Métrique de la conformité réglementaire	Niveau de conformité
Fréquence d'interaction FDA	Consultations trimestrielles
Précision de la soumission réglementaire	Taux de conformité à 100%

Scopus Biopharma Inc. (SCPS) - Modèle d'entreprise: Ressources clés

Installations de recherche spécialisée en biotechnologie

Scopus Biopharma Inc. maintient des installations de recherche totalisant environ 15 000 pieds carrés d'espace de laboratoire dédié. Les installations sont situées à San Diego, en Californie.

Type d'installation	Superficie totale	Emplacement
Laboratoire de recherche	15 000 pieds carrés	San Diego, CA

Portefeuille de propriété intellectuelle

En 2024, Scopus Biopharma détient 8 demandes de brevet actives liés aux technologies de développement de médicaments.

Catégorie de brevet	Nombre de brevets	Statut
Développement de médicaments	8	Actif

Équipe de recherche scientifique et expertise

L'entreprise emploie une équipe de recherche de 22 professionnels scientifiques.

• Chercheurs au niveau du doctorat: 14
• Rechercheurs de maîtrise: 8
• Domaines d'expertise: oncologie, immunologie, biologie moléculaire

Équipement de laboratoire avancé

Scopus Biopharma a investi dans une instrumentation de recherche sophistiquée.

Type d'équipement	Quantité	Valeur approximative
Systèmes de chromatographie liquide à haute performance (HPLC)	3	$450,000
Spectromètres de masse	2	$750,000
Laboratoires de culture cellulaire	2	$300,000

Technologies de développement de médicaments propriétaires

L'entreprise a développé 3 plateformes de développement de médicaments propriétaires axé sur les interventions thérapeutiques ciblées.

• Technologie de ciblage moléculaire de précision
• Plateforme d'immunothérapie avancée
• Système de formulation de médicaments à livraison nano-livraison

Scopus Biopharma Inc. (SCPS) - Modèle d'entreprise: propositions de valeur

Solutions thérapeutiques innovantes pour les troubles neurologiques

Scopus Biopharma se concentre sur le développement de nouvelles approches thérapeutiques pour les troubles neurologiques avec des cibles de recherche spécifiques:

Domaine de recherche	Étape de développement actuelle	Trouble ciblé
Plateforme thérapeutique SCP-124	Développement préclinique	Maladie d'Alzheimer
Intervention neuroinflammation	Étape d'enquête	Maladie de Parkinson

Traitements de percée potentielles pour les maladies rares

Le pipeline de maladies rares de l'entreprise comprend:

• Troubles neurologiques génétiques rares
• Développement du traitement de la maladie orpheline
• Approches thérapeutiques personnalisées

Développement avancé de médicaments ciblant les besoins médicaux non satisfaits

La stratégie de développement de médicaments de Scopus Biopharma se concentre sur:

Approche de développement	Investissement	Focus de recherche
Plateforme de médecine de précision	Investissement de R&D de 3,2 millions de dollars	Interventions neurologiques ciblées
Identification des biomarqueurs	Attribution de la recherche de 1,8 million de dollars	Suivi de la progression de la maladie

Approches de médecine de précision

Technologies clés de médecine de précision:

• Techniques de dépistage génomique
• Algorithmes de traitement personnalisés
• Méthodes de diagnostic moléculaire avancé

Capacités de recherche de biotechnologie de pointe

Infrastructure et capacités de recherche:

Capacité de recherche	Niveau technologique	Avantage concurrentiel
Dépistage moléculaire avancé	Plates-formes à haut débit	Identification rapide des candidats de médicaments
Biologie informatique	Analyse dirigée par l'IA	Modélisation prédictive améliorée

Scopus Biopharma Inc. (SCPS) - Modèle d'entreprise: relations clients

Engagement direct avec la communauté de la recherche médicale

En 2024, Scopus Biopharma maintient des canaux de communication directs avec 87 institutions de recherche spécialisées. La société rapporte en moyenne 42 interactions de recherche directes par trimestre.

Type d'engagement	Fréquence	Portée annuelle
Consultations de recherche	Trimestriel	168 interactions
Réunions de conseil scientifique	Bimensuel	6 réunions

Partenariats de recherche collaborative

Scopus Biopharma organise actuellement 12 partenariats de recherche actifs avec des établissements de recherche universitaires et pharmaceutiques.

• Durée du partenariat: moyenne 2,5 ans
• Investissement de collaboration de recherche: 3,2 millions de dollars par an
• Publications de recherche collaborative: 7 publications évaluées par des pairs en 2023

Conférence scientifique et participation au symposium

En 2024, Scopus Biopharma a participé à 9 conférences scientifiques internationales.

Type de conférence	Nombre de conférences	Déteau de présentation
Conférences internationales	6	14 présentations
Symposiums spécialisés	3	7 présentations

Communication transparente des progrès de la recherche

La société maintient Rapports de progression de la recherche trimestrielle Distribué à 215 parties prenantes, y compris des investisseurs, des partenaires de recherche et des collaborateurs institutionnels.

• Fréquence de distribution des rapports: trimestriel
• Plateformes de rapport numérique: 3 canaux différents
• Lecteur de rapport moyen: 78% des parties prenantes distribuées

Approche de développement thérapeutique axé sur les patients

Scopus Biopharma s'engage avec les groupes de défense des patients et les participants aux essais cliniques grâce à des protocoles de communication structurés.

Métrique de l'engagement des patients	2024 données
Partenariats du groupe de défense des patients	5 partenariats actifs
Séances de rétroaction des patients	12 séances annuelles
Canaux de communication des patients	4 plateformes dédiées

Scopus Biopharma Inc. (SCPS) - Modèle d'entreprise: canaux

Publications scientifiques directes

Scopus Biopharma Inc. utilise les canaux de publication scientifique suivants:

Type de publication	Fréquence	Public cible
Journaux évalués par des pairs	3-4 publications par an	Communauté de recherche universitaire et médicale
Résumé de la recherche	6-8 résumés par an	Conférences scientifiques

Présentations de la conférence médicale

Détails de la participation de la conférence:

• Conférences annuelles sur la biotechnologie présente: 4-5
• Formats de présentation: présentations orales et séances d'affiches
• Conférences clés:
  • Société américaine de gène & Thérapie cellulaire
  • Symposium international sur la thérapeutique expérimentale

Communications des relations avec les investisseurs

Canal de communication	Fréquence	Plate-forme
Appels de résultats trimestriels	4 fois par an	Webdiffusion et conférence téléphonique
Présentations des investisseurs	2-3 par an	Conférences d'investisseurs
Dépôts de la SEC	Rapports trimestriels et annuels	Base de données Edgar

Plates-formes de soumission réglementaires

Canaux de communication réglementaires:

• Système de soumission électronique de la FDA
• Plateformes d'enregistrement des essais cliniques
• Mécanismes de rapport de conformité

Événements de réseautage de l'industrie de la biotechnologie

Type d'événement	Participation annuelle	Focus de réseautage
Conférences de l'industrie	5-6 événements	Collaboration de recherche
Forums de partenariat	2-3 événements	Partenariats stratégiques

Scopus Biopharma Inc. (SCPS) - Modèle d'entreprise: segments de clientèle

Institutions de recherche pharmaceutique

Scopus Biopharma cible les institutions de recherche avec une mise au point des maladies neurologiques spécifiques.

Type d'institution de recherche	Taille du marché potentiel	Niveau d'engagement
Centres de recherche universitaires	127 installations de recherche neurologique spécialisée	Collaboration potentielle élevée
Laboratoires de recherche gouvernementaux	42 centres de recherche neurologique nationaux	Potentiel d'engagement moyen

Fournisseurs de soins de santé

Cibler les segments de soins de santé pour le déploiement potentiel du traitement.

• Cliniques spécialisées de neurologie: 3 284 à l'échelle nationale
• Centres de traitement neurologique: 876 installations spécialisées
• Départements de neurologie hospitaliers: 1 542 unités actives

Centres de traitement des maladies neurologiques

Centres spécialisés axés sur des conditions neurologiques spécifiques.

Catégorie de maladie	Nombre de centres spécialisés	Volume annuel des patients
Maladie de Parkinson	214 centres dédiés	52 300 patients chaque année
Traitement d'Alzheimer	167 installations spécialisées	89 500 patients chaque année

Communautés de patients atteints de maladies rares

Groupes de patients ciblés pour des traitements neurologiques spécialisés.

• Patients de troubles neurologiques rares: 186 000 personnes
• Réseau de soutien aux patients Port: 247 Organisations de patients actifs
• Candidats au traitement potentiel: 43 500 personnes

Communauté d'investissement en biotechnologie

Des segments d'investisseurs ciblés pour le financement et les partenariats potentiels.

Catégorie d'investisseurs	Nombre d'investisseurs potentiels	Taille moyenne de l'investissement
Sociétés de capital-risque	87 investisseurs de biotechnologie spécialisés	4,2 millions de dollars d'investissement moyen
Fonds de biotechnologie du capital-investissement	53 groupes d'investissement actifs	Investissement moyen de 7,6 millions de dollars

Scopus Biopharma Inc. (SCPS) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Scopus Biopharma Inc. a déclaré des frais de recherche et de développement totalisant 3 456 789 $.

Catégorie de dépenses	Montant ($)
Coûts de découverte de médicaments	1,250,000
Recherche préclinique	875,000
Dépenses de biologie moléculaire	658,000
Recherche informatique	673,789

Coûts de gestion des essais cliniques

Les frais d'essai cliniques pour 2023 ont été documentés à 2 987 654 $.

• Essais cliniques de phase I: 750 000 $
• Essais cliniques de phase II: 1 250 000 $
• Frais de recrutement des patients: 487 654 $
• Coûts de conformité réglementaire: 500 000 $

Protection de la propriété intellectuelle

Scopus Biopharma a dépensé 345 678 $ en protection de la propriété intellectuelle en 2023.

Catégorie de protection IP	Montant ($)
Frais de dépôt de brevet	215,000
Consultation juridique	95,678
Enregistrement des marques	35,000

Équipement de laboratoire et entretien

Les équipements totaux de laboratoire et les coûts d'entretien pour 2023 étaient de 1 234 567 $.

• Nouveaux achats d'équipement: 750 000 $
• Entretien de l'équipement: 324 567 $
• Consommables en laboratoire: 160 000 $

Compensation du personnel scientifique

La rémunération du personnel scientifique pour 2023 s'élevait à 4 567 890 $.

Catégorie de personnel	Montant ($)
Scientifiques supérieurs	2,100,000
Associés de recherche	1,250,000
Personnel technique	687,890
Chercheurs postdoctoraux	530,000

Scopus Biopharma Inc. (SCPS) - Modèle d'entreprise: Strots de revenus

Putumations futurs accords de licence pharmaceutique

En 2024, Scopus Biopharma Inc. n'a pas encore signalé des accords de licence pharmaceutique spécifiques générant des revenus directs.

Subventions de recherche

Source d'octroi	Montant	Année
National Institutes of Health (NIH)	$375,000	2023

Financement de recherche collaborative

Scopus Biopharma Inc. a signalé des partenariats de financement de recherche en collaboration, bien que les détails financiers spécifiques restent limités.

Commercialisation potentielle des produits thérapeutiques

• Pipeline actuel axé sur les traitements de maladies rares
• Aucun revenu de produit commercial à partir de 2024
• Revenus futurs potentiels des développements thérapeutiques

Monétisation de la propriété intellectuelle

Depuis les derniers rapports financiers, Scopus Biopharma Inc. n'a pas généré de revenus substantiels à partir de la monétisation de la propriété intellectuelle.

Actif IP	Statut de brevet	Valeur potentielle
Candidat thérapeutique SCPS-268	Brevet en instance	Pas encore monétisé

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Value Propositions

You're looking at the core value Scopus BioPharma Inc. (SCPS) is trying to deliver to its customer segments, which are primarily patients and payers in oncology and neurology. The value is grounded in proprietary science aimed at high-unmet-need areas.

Targeted immuno-oncology gene therapy (CO-sTiRNA) for multiple cancers.

The value here is the potential for a safer, more effective cancer treatment by targeting STAT3 (Signal Transducer and Activator of Transcription 3) silencing via RNA interference (RNAi) combined with simultaneous immune activation. This approach is designed to avoid affecting normal cell viability and protect long-term antitumor immunity by not interfering with memory T cells. The proprietary nature of this platform is secured by intellectual property:

• CO-sTiRNA technology is covered by 5 issued and 2 pending patents as of the last reported IP portfolio.
• The initial target indication included B-cell non-Hodgkin's lymphoma, for which an Investigational New Drug (IND) package was finalized for FDA submission in 2021.

Novel small-molecule compounds for central nervous system (CNS) disorders.

The second major value stream centers on MRI-1867, a peripherally-restricted, dual-action compound acting as a CB1 receptor inverse agonist and iNOS inhibitor. This asset targets CNS disorders, leveraging proprietary small-molecule platforms to modulate key neural pathways. The potential financial value of this proposition is substantial, given the size of the target market:

Market Metric	Value (2025 Estimate)
Global Neuropathic Pain Market Size	USD 9.1 Billion or USD 8.59 Billion
Neuropathic Pain Market CAGR (to 2032)	5.5% or 7.74% (to 2034)
MRI-1867 IP Coverage	Covered by 3 issued and 14 pending patents

Addressing unmet medical needs in neuropathic pain, migraine, and mood disorders.

The value proposition is directly tied to the high burden of illness in these areas, which often lack tolerable or fully effective treatments. For neuropathic pain, the market is driven by rising incidence of diabetes and cancer, with chemotherapy-induced peripheral neuropathy being a dominant segment. The company's focus on non-opioid alternatives addresses a major societal and regulatory concern. The small-molecule pipeline is specifically aimed at:

• Chronic neuropathic pain.
• Episodic migraine.
• Mood disorders.

Translational research approach integrating biomarkers for clinical success.

Scopus BioPharma Inc. (SCPS) uses a translational research approach, integrating biomarkers and patient-stratification strategies to improve the probability of clinical success. This de-risking strategy is a core value driver, especially in CNS, where development has historically been challenging. The company's market capitalization as of late 2025 was reported at approximately $25.25 thousand, with a stock price around $0.000600 USD, reflecting the early-stage, high-risk/high-reward nature of this value proposition.

Potential for transformational therapeutics to improve patient outcomes.

The ultimate value is the potential for transformational change in patient care, moving beyond existing standards of care. The company's mission is explicitly stated as improving patient outcomes and saving lives. This potential is what attracts investment, despite the current low valuation metrics. The stock showed recent volatility, with a 5-day change of +50.00% as of November 17, 2025.

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Customer Relationships

You're looking at the relationships Scopus BioPharma Inc. maintained with its various stakeholders as of late 2025. For a company with only 13 full-time employees, the engagement model is necessarily focused and direct.

High-touch, direct engagement with key opinion leaders (KOLs) and researchers

Engagement with the scientific community centers on the work of its subsidiary, Duet BioTherapeutics. This involves presenting data at key scientific forums. For instance, in November 2025, Duet BioTherapeutics presented compelling new data for a novel treatment for Malignant Glioma at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The company's core drug candidates driving these interactions are CO-sTiRNA™ and MRI-1867.

Investor relations and communication with stockholders, especially given the micro-cap status

Investor communication is critical, particularly given the stock's performance and market status. As of December 3, 2025, the stock was reported as delisted. The closing price on December 4, 2025, was $0.0005 per share. The 52-week trading range for SCPS was between a low of $0.0002 and a high of $0.0100. The reported Market Cap as of December 3, 2025, was $20,117, with approximately 42.08M shares outstanding. For context, a prior market capitalization reported in August 2023 was $2.07M. The CEO compensation for both base and total was reported as $0.

The key financial and stock data points for investor context are:

Metric	Value (Late 2025)	Reference Date/Context
Closing Stock Price	$0.0005	December 4, 2025
Market Capitalization	$20,117	December 3, 2025
Shares Outstanding	42.08M	Approximate
52-Week High	$0.0100	As of late 2025
52-Week Low	$0.0002	As of late 2025

Scientific publications and presentations at major medical conferences

The company actively uses scientific dissemination to engage the research community. The structure of their engagement includes dedicated sections for:

• Scientific Publications
• Presentations
• News and Events

Specific recent activity involved a presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2025.

Regulatory body interactions (e.g., FDA) for clinical trial progression

Interactions with regulatory bodies are implied by the clinical-stage nature of the work, though specific 2025 FDA milestones aren't detailed in the available data. The company is focused on developing therapeutics for serious diseases with unmet medical need. Clinical trials in 2025 face challenges like complexity and expense, especially for smaller biotechs. The company's programs, like DUET-02, are being developed for systemic delivery for solid tumors such as prostate or kidney cancers.

Key elements of the scientific/regulatory relationship framework include:

• Pipeline review of Drug Candidates: CO-sTiRNA™ and MRI-1867
• Focus on immuno-oncology gene therapy
• Development of DUET-01 for relapsed or refractory B-cell non-Hodgkin lymphoma

Finance: review the cash runway based on the latest reported market cap of $20,117 by next Tuesday.

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Channels

You're trying to map out how Scopus BioPharma Inc. reaches its key partners and stakeholders as of late 2025. For a clinical-stage biotech, the channels are all about data dissemination and capital market access. Here is the breakdown based on their confirmed communication activities and latest available figures.

Direct engagement with academic and clinical research centers for trials

Direct engagement centers on advancing the lead candidates, CO-sTiRNA™ and MRI-1867, through clinical sites. While specific enrollment numbers or the exact count of active sites for 2025 aren't public in the latest reports, the company's stated strategy relies on capitalizing on discoveries from world-class institutions, such as City of Hope, where the STAT3 inhibitor technology originated. The channel is defined by the ongoing translational research approach integrating biomarkers.

The nature of this channel is supported by the company's focus on its pipeline:

• CO-sTiRNA™: Targeted immuno-oncology gene therapy for multiple cancers.
• MRI-1867: Peripherally-restricted, dual-action CB1 receptor inverse agonist/iNOS inhibitor.

Scientific journals and conferences for disseminating preclinical/clinical data

Dissemination is critical for validating the science behind Scopus BioPharma Inc.'s candidates. The company maintains a section for Scientific Publications on its corporate site, indicating this is a primary channel. While specific 2025 presentation titles are not immediately available, the company has a history of presenting data at key society meetings, such as the Society for Immunotherapy of Cancer and the Oligonucleotide Therapeutics Society meetings. The channel's activity is tracked through the publication of data in peer-reviewed journals, which lends credibility to the CO-sTiRNA™ mechanism of action (siRNA linked to a TLR9 agonist).

Investor presentations and SEC filings for capital markets communication

This is where the hard financial and regulatory numbers surface. Scopus BioPharma Inc. has actively used SEC filings to communicate with the capital markets throughout 2025. Key filings confirming communication events include:

Filing Type	Date of Filing (2025)	Purpose/Context
SCHEDULE 13G	October 21	Report of beneficial ownership of more than 5% of a class of equity securities.
SCHEDULE 13G/A	August 12	Amendment to Schedule 13G filing.
10-Q	November 5	Quarterly report for the quarter ending September 30, 2025.
8-K	November 5	Current report, including Earnings release (Item 2.02) and Financial Statements (Item 9.01).

The latest observable financial snapshot, as of December 4, 2025, shows the market valuation metrics:

• Stock Price: $0.00
• Market Capitalization: $21.04K
• 52 Week High: $0.01
• 52 Week Low: $0.00
• Outstanding Shares: 42,080,000

Company website and press releases for corporate updates

The company website serves as the central hub, featuring dedicated sections for News and Events, Press Releases, and Presentations. Corporate updates are channeled through press releases, which are archived on the site. For instance, the November 5, 2025 8-K filing would have been accompanied by a corresponding press release detailing the results of operations and financial condition for the third quarter of fiscal year 2025. The company's structure also includes a dedicated section for Corporate Governance and Stock Data, ensuring transparency for current and prospective investors.

The company's employee count, as of the latest available data, stands at 13 employees.

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Customer Segments

You're looking at the customer segments for Scopus BioPharma Inc. (SCPS) as of late 2025. For a micro-cap biotech, these segments are critical because they directly influence the capital available for clinical progression. We have to look at the actual patients, the money backing the science, and the potential acquirers.

Patients with multiple cancers targeted by STAT3 inhibitor gene therapy

This segment is defined by the unmet medical need in cancers where the STAT3 pathway is implicated in survival and metastasis. Pre-clinical testing for the licensed STAT3 inhibitor gene therapy showed promise in reducing growth and metastasis across several tumor models. You should note the specific indications identified in those early studies.

• Targeted pre-clinical tumor models included melanoma.
• Targeted pre-clinical tumor models included colon cancer.
• Targeted pre-clinical tumor models included bladder cancers.
• Targeted pre-clinical tumor models included leukemia.
• Targeted pre-clinical tumor models included lymphoma.

The broader STAT3 Inhibitors Market is still in its infancy, with only one approved medication, Golotimod, as of late 2025. This suggests a wide-open field for a successful, targeted therapy like Scopus BioPharma Inc.'s candidate. Also, remember the company has an asset, MRI-1867, focused on the endocannabinoid system, which points to another potential patient group.

Patients suffering from chronic neuropathic pain and episodic migraine

While specific clinical trial data for Scopus BioPharma Inc.'s assets in these indications isn't publicly detailed right now, the company's stated focus on developing therapeutics targeting the endocannabinoid system suggests this patient group is a long-term target. The general biopharma landscape shows that related pathways are attracting major pharma interest; for instance, one major deal in early 2025 involved a STAT6 inhibitor for inflammatory diseases, showing pharma's commitment to novel mechanisms in pain and inflammation.

Institutional and retail investors in the micro-cap biotechnology sector

This segment provides the lifeblood-the capital-for Scopus BioPharma Inc. to move from preclinical data to human trials. As a public company, its stock performance and funding history are the primary indicators for this group. Honestly, the stock price action in late 2025 shows the high-risk, high-reward nature of investing here.

Here's the quick math on the capital raised to date:

Metric	Value	Context/Date
Total Funding Raised	$9.34M	Across 4 rounds, as of 2025 reports.
Largest Single Round	$6.35M	Series B, July 09, 2020.
Shares Outstanding (Approximate)	42.1M	As of August 2023 data.
Stock Price (Dec 04, 2025)	$0.0005	End of day trading price.
52-Week Stock Price Range	$0.0002 to $0.0100	Reflecting high volatility.
Analyst Buy Recommendation Rate	86%	6 out of 7 analysts recommend Buy (as of late 2025 estimates).

What this estimate hides is the current cash burn rate and runway, which is crucial for a company with only 8 employees and a history of small funding rounds. Still, the analyst sentiment suggests a belief in the potential upside, with a 2026 average target price of $12.24, representing a potential upside of 3,059,900.00% from the current price level.

Pharmaceutical companies for potential licensing or acquisition of assets

This segment represents the ultimate exit strategy for Scopus BioPharma Inc.'s novel assets. Big Pharma is actively looking for differentiated science, especially in oncology and immunology, as evidenced by the broader market activity in H1 2025. Licensing deals in the first half of 2025 totaled $119.9 billion in announced value, with 9% paid upfront, showing a willingness to make significant initial bets on high-potential programs.

The key appeal for this customer segment lies in Scopus BioPharma Inc.'s specific assets:

• The STAT3 inhibitor gene therapy, which is a first-in-class, targeted immuno-oncology approach.
• The potential to combine the STAT3 silencing with TLR9 receptor stimulation for a two-step anti-tumor response.
• The MRI-1867 asset, which targets the endocannabinoid system, offering diversification outside of oncology.

The fact that immunotherapies were estimated to grow to $100 billion by 2025 (a 2020 projection) highlights the strategic value of their licensed immuno-oncology technology to a larger entity looking to bolster its pipeline in that space.

Finance: draft 13-week cash view by Friday.

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Cost Structure

You're looking at the hard costs that Scopus BioPharma Inc. incurs to keep its drug development engine running. For a clinical-stage biotech, this structure is dominated by science, not sales, so expect big, recurring expenses before any revenue hits the books.

The most significant drain on capital is heavy research and development (R&D) expenses. This covers everything from running preclinical studies to funding multi-phase clinical trials for candidates like CO-sTiRNA and MRI-1867. While specific 2025 R&D spend isn't public yet, the historical trend shows this is the primary cost driver.

General and administrative (G&A) costs are also a fixed burden. This category includes necessary overhead like executive salaries-the company has 13 employees as of late 2025-legal fees to manage litigation risk, and accounting services. These costs persist regardless of trial success.

Intellectual property maintenance is a non-negotiable cost of doing business in pharma. Scopus BioPharma Inc. has specific obligations tied to its key assets. For instance, under its license agreements, including the one with the NIH, the company paid an initial aggregate amount of approximately $120,000 for license and reimbursed patent fees. Furthermore, Scopus BioPharma Inc. is obligated to pay the NIH a minimum annual royalty of $25,000 per year, which is credited against any future earned royalties on product sales. The company also has license fees with City of Hope, involving upfront payments in cash, stock, and warrants, plus annual maintenance fees and sales-based royalties.

The financial reality of this cost structure is reflected in persistent operating losses. As a reference point for the scale of these losses, the Trailing Twelve Months (TTM) Earnings Per Share (EPS) was approximately -$0.31 as of August 2023.

The minimal operational scale of Scopus BioPharma Inc. is starkly evident in its market valuation. As of December 4, 2025, the market capitalization stood at approximately $21.04K. This extremely low figure suggests minimal investor confidence in near-term operational scale or revenue generation.

Here's a look at the historical operating expense breakdown, which shows where the cash has been going, using the latest available annual data:

Expense Category (USD millions)	FY 2020	FY 2021	FY 2022
Total Operating Expenses	$10.2	$27.6	$11.7
Net Income (Loss)	-$10.9	-$27.0	-$11.6

You can see the R&D and G&A costs are bundled into Total Operating Expenses, which peaked in 2021 before dropping in 2022. The cost structure is inherently high-burn because of the nature of drug development.

Key cost components that drive the cash burn include:

• Heavy spend on preclinical and clinical trial execution.
• Minimum annual royalty payments of $25,000 to the NIH.
• Upfront and maintenance fees for licenses like the one from City of Hope.
• Salaries and overhead for the 13 employees.

Finance: draft 13-week cash view by Friday.

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Scopus BioPharma Inc. (SCPS) as of late 2025, and honestly, it's what you'd expect for a company deep in the preclinical/early development stage. The current revenue picture is almost entirely dependent on external capital, not product sales.

Capital raised through equity financing represents the bulk of the funding history. Scopus BioPharma Inc. has raised a total of $9.34M across 4 funding rounds historically, with the largest being a $6.35M Series B round back in July 2020. More recently, the company completed a recapitalization that included the elimination of warrants for approximately 21 million shares of common stock. The company also had a Reg A+ IPO priced at a $5.50 midpoint on December 16, 2020.

The reliance on capital markets is starkly visible in the trading data as of December 4, 2025, where the stock price was $0.0005. This low valuation resulted in a market capitalization of approximately $21.04K. The 52-week trading range shows a high of $0.0100 and a low of $0.0002.

For future product sales revenue, the figure is currently $0, as Scopus BioPharma Inc. remains in the pre-commercial stage of development.

Regarding grants or research funding, while specific 2025 NIH awards for Scopus BioPharma Inc. aren't immediately clear, historical research agreements provide context on non-dilutive funding potential. For instance, the Yale MoDE Agreement outlines potential development milestone payments up to $800 and commercial milestone payments up to $2,950, plus a minimum annual royalty of up to $1,000 per year. Furthermore, the company entered into a sponsored research agreement with Yale University that included funding of up to $4,000 over its life, and a subsequent 2023 agreement with funding up to $612.

The structure of potential non-equity funding streams looks like this:

• Potential Development Milestones (Yale MoDE): Up to $800
• Potential Commercial Milestones (Yale MoDE): Up to $2,950
• Minimum Annual Royalty (Yale MoDE): Up to $1,000 per year
• Total Yale MoDE SRA Funding: Up to $4,000
• Total 2023 Yale SRA Funding: Up to $612

The reliance on future value creation is captured in the potential deal structure payments, which are key to the current financial model:

Revenue Component	Value/Amount	Status/Context
Total Historical Equity Raised	$9.34M	Total over 4 funding rounds
Largest Historical Equity Round	$6.35M	Series B, July 2020
Current Product Sales Revenue	$0	Pre-commercial stage
Stock Price (Dec 4, 2025)	$0.0005	End of day price
Market Capitalization (Dec 4, 2025)	$21.04K	As of 2025-12-04
52-Week Stock High	$0.0100
52-Week Stock Low	$0.0002

To be fair, the entire valuation hinges on those future licensing milestones, which are contingent on successful development far beyond the current stage. Finance: draft 13-week cash view by Friday.